The National Institutes of Health on Wednesday updated its COVID-19 treatment guidelines for patients with mild to moderate forms of COVID-19 who are at high risk for disease progression. The new guidelines now include the recently authorized antivirals developed by Pfizer Inc. and Merck & Co. Inc. /Ridgeback Biotherapeutics, note that GlaxoSmithKline and Vir Biotechnology Inc.’s sotrovimab is the only monoclonal antibody that is thought to be effective against omicron, and have added a three-day course of Gilead Sciences Inc.’s Veklury as a treatment option. The panel suggests that clinicians first use Pfizer’s Paxlovid, then sotrovimab, then Veklury, and the final option should be molnupiravir, which is the Merck/Ridgeback drug.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
